VANCOUVER, BC, August XX, 2022 – PanGenomic Health Inc. (CSE:NARA) (the "Company" or "PanGenomic Health") is pleased to announce that its Nara app is now available for download in North America on the Apple App Store and the Google Play Store. As one of Canada's first publicly-traded benefit companies, PanGenomic Health is committed to providing consumers with personalized information about evidence-based natural remedy solutions to support mental health in Canada.
"People are taking more control over their personal health decisions, and need access to evidence-based information about mental health solutions delivered in a consumer-friendly manner," said Robert Nygren, Executive Chair of PanGenomic Health. " With our Nara app, users can access, share and discuss trusted sources of information about treatments for mental illnesses in order to educate themselves about their own use of pharmaceutical and natural remedy medications."
In a widely reported study published this month in Molecular Psychiatry led by researchers from University College London, the UK, Italian and Swiss researchers carried out a systematic review of the evidence for the serotonin chemical imbalance theory of depression. The researchers found that "it is impossible to say that taking SSRI antidepressants is worthwhile, or even completely safe. People need all this information to make informed decisions about the safety of antidepressants and whether or not to take antidepressants."
The free Nara app includes a plant medicine library, curated articles, such as the SSRI study, an online peer community and access to DNA insight reports to learn how genetics may impact the effectiveness of natural remedy solutions.
About PanGenomic Health
PanGenomic Health Inc. is a precision health company that has developed a self-care digital platform to deliver personalized, evidence-based information about natural treatments to support mental health. Registered as a public benefit corporation, the Company's mission is to improve the overall health and wellness of people by providing a technology platform that identifies natural treatments tailored to the health profile of each individual.
For more information, please contact:
Jerry Lai, Investor Relations
PanGenomic Health Inc.
778 743 4642
This news release includes certain statements that may be deemed “forward-looking statements”, including statements respecting the services to be provided by PanGenomic and the consideration to be paid to PanGenomic. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “would”, “project”, “should”, “believe” and similar expressions are intended to identify forward looking statements. Although PanGenomic believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward looking statements because PanGenomic can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this News Release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in PanGenomic’s disclosure documents which can be found under PanGenomic’s profile on www.sedar.com.
The Canadian Securities Exchange has neither approved nor disapproved the information contained herein and does not accept responsibility for the adequacy or accuracy of this news release.